Biomind Labs Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMNDF research report →
About the company
Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression.
- CEO
- Alejandro Antalich
- IPO
- 2021
- Employees
- 5
- HQ
- Canelones, UY
Price Chart
- Market Cap
- $861.05K
- P/E
- -0.96
- P/S
- 0.00
- P/B
- -0.55
- EV/EBITDA
- -1.85
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 60.67%
- ROIC
- 94.40%
- Revenue
- $0 · 0.00%
- Net Income
- $-865,298 · -232.19%
- EPS
- $-0.01 · -226.47%
- Op Income
- $-861,418
- FCF YoY
- 80.61%
- 52W High
- $0.13
- 52W Low
- $0.01
- 50D MA
- $0.11
- 200D MA
- $0.07
- Beta
- 7.32
- Avg Volume
- 169
Get TickerSpark's AI analysis on BMNDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BMNDF coverage
Recent articles, reports, and earnings notes.
No research on BMNDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BMNDF report →Similar companies
Peers in the same neighborhood.